SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for epidural injection for the management of lumbar radicular pain) and ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components, announce that ProMed Pharma has acquired SpineThera’s cGMP manufacturing operational assets. ProMed Pharma also obtained an option to license SpineThera’s microsphere intellectual property with the potential to sub-license to ProMed Pharma’s customers.
Read the full article: ProMed Pharma Acquires SpineThera Manufacturing Capabilities //
Source: https://www.businesswire.com/news/home/20240403291054/en/ProMed-Pharma-Acquires-SpineThera-Manufacturing-Capabilities-and-an-Option-to-License-Intellectual-Property